Back to discover
Disease

Urogenital Neoplasms

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHUrogenital Neoplasms
3
Publications
18
Clinical trials
3
Related conditions
1
Related proteins
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Research2024-07-02Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Research2017-11-01Advances in anatomic pathology

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Research2015-06-18PloS one

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Clinical Milestones5View
Results posted 2
Results expected 1
Recently completed 1
Other updates 1
Activity timeline5

Clinical trials

16 sponsors · 0 new · 0 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
3
Late-stage
6
Completed
Late-stage studies

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

Phase 4 · Recruiting · VA Greater Los Angeles Healthcare System

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 · Active, not recruiting · Eli Lilly and Company

A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)

Phase 3 · Withdrawn · Medical Enterprises Europe B.V.
Recruiting

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

Phase 4 · Recruiting · VA Greater Los Angeles Healthcare System

A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 · Recruiting · Sheba Medical Center

A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Phase 2 · Recruiting · The Netherlands Cancer Institute

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

Phase 1/2 · Recruiting · Blue Earth Therapeutics Ltd

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Phase 1/2 · Recruiting · Marengo Therapeutics, Inc.
Recently completed

High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy

Phase 2 · Completed · Alessandro D'Agnolo

Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma

Phase 1/2 · Completed · NanOlogy, LLC

An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy

Phase 2 · Completed · Novartis Pharmaceuticals

A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Phase 2 · Completed · Eli Lilly and Company

A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma

Phase 2 · Completed · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma

Phase 2 · Completed · Pharmacyclics LLC.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20152024
Most influential

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Advances in anatomic pathology · 2017 · 607 cites

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

PloS one · 2015 · 350 cites

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 18 cites
Recent publications

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 18 cites

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Advances in anatomic pathology · 2017 · 607 cites

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

PloS one · 2015 · 350 cites
Major themes6
  • Anilides1
  • Antineoplastic Combined Chemotherapy Protocols1
  • Ipilimumab1
  • Nivolumab1
  • Pyridines1
  • Urogenital Neoplasms1
Leading journals3
  • Advances in anatomic pathology1
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
  • PloS one1
Leading researchers8
  • Adams S1
  • Agarwal PK1
  • Akbulut D1
  • Allison KH1
  • Allory Y1
  • André F1
  • Apolo AB1
  • Badve S1
Affiliations (unnormalised)6
  • Center for Cancer Research1
  • Center for Onco-Immunology1
  • City of Hope Comprehensive Cancer Center1
  • Clinical Center1
  • College of Medicine1
  • Herbert Irving Comprehensive Cancer Center1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Nivolumab2

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Carcinoma, Non-Small-Cell Lung2Lung Neoplasms2Melanoma2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.

Identifiers
MeSHUrogenital Neoplasms
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.